Compare Dover Corp (DOV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Zoetis Inc — how do they compare? Dover Corp trades at $189.15 (market cap $25.45B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Zoetis Inc for 70 Days on average.
| DOV | ZTS | |
|---|---|---|
Market Cap | $25.45B | $30.20B |
Volume | 661,758 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $233.31 | $147.53 |
52-Week Low | $161.16 | $69.09 |
Typical Hold Time | 73 Days | 70 Days |
Enterprise Value | $26.95B | $37.76B |
Dividend Yield | 1.11% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.83, up 0.29% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $2.74 exceeding expectations, supported by robust profitability margins including 39.58% gross margin and 13.48% net income margin. Recent acquisitions and product launches demonstrate ongoing business expansion.
Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential. Key risks include technical weakness and cyclical industrial exposure, but strong cash flow generation and dividend history provide stability. The combination of earnings momentum and institutional support suggests long-term value despite near-term technical headwinds.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
